An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina’s history of leadership as foundation for MRD market SAN DIEGO, May 28, 2026 /PRNewswire/ –…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
